

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 62252

Title: Genotype 3-hepatitis C virus' last line of defense

Reviewer's code: 04762027

Position: Peer Reviewer

Academic degree: PhD

Professional title: Postdoc

Reviewer's Country/Territory: United Kingdom

Author's Country/Territory: Poland

Manuscript submission date: 2021-01-11

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-01-12 12:30

Reviewer performed review: 2021-01-12 14:20

Review time: 1 Hour

Scientific quality	[<input checked="" type="radio"/>] Grade A: Excellent [<input type="radio"/>] Grade B: Very good [<input type="radio"/>] Grade C: Good [<input type="radio"/>] Grade D: Fair [<input type="radio"/>] Grade E: Do not publish
Language quality	[<input checked="" type="radio"/>] Grade A: Priority publishing [<input type="radio"/>] Grade B: Minor language polishing [<input type="radio"/>] Grade C: A great deal of language polishing [<input type="radio"/>] Grade D: Rejection
Conclusion	[<input checked="" type="radio"/>] Accept (High priority) [<input type="radio"/>] Accept (General priority) [<input type="radio"/>] Minor revision [<input type="radio"/>] Major revision [<input type="radio"/>] Rejection
Re-review	[<input type="radio"/>] Yes [<input checked="" type="radio"/>] No
Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No

SPECIFIC COMMENTS TO AUTHORS

Congratulations to the author on presenting a manuscript that provides an exhaustive list of therapies on the HCV arena, especially genotype 3. For a non-clinician reader, this manuscript would be a useful one to read and understand the impact of DAAs on the HCV treatment.

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 62252

Title: Genotype 3-hepatitis C virus' last line of defense

Reviewer's code: 05466134

Position: Peer Reviewer

Academic degree: MBBS, MD

Professional title: Academic Fellow

Reviewer's Country/Territory: United States

Author's Country/Territory: Poland

Manuscript submission date: 2021-01-11

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-01-14 12:40

Reviewer performed review: 2021-01-14 20:09

Review time: 7 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgooffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

It was a pleasure reviewing this paper written by Dorota Zarębska-Michaluk. The author has provided an precise review of the available literature regarding treatment of Genotype 3 HCV infection. All references were cross checked and were appropriately used. The relation between hepatic steatosis and GT3 infection was explained with appropriate use of references. In the current DAA era, GT-3 has emerged as the most difficult GT to treat. Mayvret and Eplclusa are the initial treatment options for patients that are treatment Naïve without and with cirrhosis, whereas Epclusa is preferred for retreatment in patients without cirrhosis and Mavyret or Vosevi in patients with cirrhosis. This paper will be interesting to the readers, and especially who are interested in knowing the pathway that lead to development of these new strategies for treatment of HCV-GT-3 infection. Following are some minor comments. The core tip has similar sentences as the abstract. Recommend summarizing and rephrasing the sentences to give uniqueness to the core tip section rather than copying information from the abstract already available to the readers. Recommend using more appropriate terminologies. Consider replacing words like "good one", "bad one" or "naughty one". Correction: old: "there is a still room for improvement" new: "there is still room for improvement" Please spell out abbreviation CHC in following sentence "The strong association between GT3 infection and end-stage liver disease was documented in HCV-infected drug abusers in France and confirmed by a population-based study in a cohort of native Alaskans with CHC[30,31]." Please spell out abbreviation SoC in following sentence: The addition of SOF to pegIFN α and RBV (SPR) leads to better outcomes when compared to SoC, regardless of liver fibrosis and history of previous antiviral therapy. I hope these comments help author to improve their manuscript.